SPRC reported a notable stock rise today, with SciSparc trading at $3.0497 as of 10:40 AM EST. The strong increase highlights growing market confidence as SciSparc moves into the expanding GERD device segment. SPRC strengthens its position by advancing its strategy through a new intellectual property acquisition.
SciSparc completed a binding term sheet with Xylo Technologies to obtain patents, trademarks, and medical device rights. This action allows SciSparc to pursue commercialization of the MUSE endoscopic system, which supports minimally invasive GERD treatment. SciSparc aims to scale its reach by forming regional distribution agreements across high-growth territories.
The recent stock momentum reflects rising expectations for SciSparc as it diversifies beyond clinical-stage pharmaceutical activity. SPRC looks to build revenue streams through new medical technologies, reinforcing growth ambitions. SciSparc positions itself to capture value in a market expected to expand gradually.
Expansion Through Strategic Technology Acquisition
SPRC plans to issue ordinary shares representing 19.99% of its capital to Xylo upon closing. The company may also opt to issue pre-funded warrants, providing flexibility during the transaction. The assets obtained include full ownership of the MUSE system and related intellectual property.
SciSparc expects to replicate Xylo’s prior commercialization structure to reach major medical markets. In 2019, Xylo secured $3 million upfront from a China licensing agreement, and SciSparc now seeks similar partnerships abroad. SciSparc targets North America, Europe, and Latin America, where demand continues to rise.
The MUSE™ system is designed for transoral fundoplication, enabling GERD symptom relief through a non-surgical method. SciSparc anticipates increased adoption due to growing preference for minimally invasive procedures. This technology aligns with long-term healthcare trends focused on efficiency and patient recovery.
Market Outlook and Industry Context
According to industry research, the global GERD device market reached $2.5 billion in 2024. It is projected to reach $3.03 billion by 2030 at a CAGR of 3.24% from 2025. Consequently, SciSparc aligns with a sector demonstrating stable demand and gradual growth.
SciSparc’s expansion comes amid broader healthcare innovations targeting chronic digestive conditions. The company supports continued development through its majority-owned subsidiary, NeuroThera Labs Inc. This move signals SciSparc’s intent to extend beyond pharmaceuticals into high-value medical equipment.
SciSparc remains subject to completion of definitive agreements before finalizing the acquisition. The company maintains confidence in closing terms without regulatory complications. In the meantime, SciSparc continues advancing toward commercial readiness while capitalizing on current momentum.
Stock Performance and Strategic Position
SciSparc stock stabilized around $3.05 following initial volatility during market open. The trading surge indicates stronger recognition of the company’s new strategic direction. SPRC reinforces long-term positioning through technological expansion and wider geographic outreach.
SciSparc develops pharmaceutical candidates and now broadens ambitions within high-potential medical device markets. Its latest acquisition effort supports diversification and revenue acceleration. SPRC demonstrates proactive steps to strengthen competitiveness and market presence.
SciSparc plans further updates as negotiations progress and commercialization strategies unfold. The company remains focused on execution while maintaining regulatory compliance. SPRC moves forward with momentum as it transitions into the GERD device industry.